Released Nov 13, 2025, before the open
10-Q filed Nov 13, 2025, 44 days after period end · 0001104659-25-110824
Q3 2025 · 10-Q
Revenue$17.85M$17.85M −0.6% vs Q3 2024+14.0% vs Q2 2025
Net Income$2.36M$2.36M −27.2% vs Q3 2024+1,336.0% vs Q2 2025
EPS Diluted$0.03$0.03 ±0.0% vs Q3 2024no prior Q2 2025 on file
Operating Income$2,131,000−46.6%
Operating Cash Flowderived-$3,732,000N/M
Free Cash Flowderived-$4,230,000N/M
Margins · derived
Operating margin11.9%−10.3 pt vs Q3 2024
Net margin13.2%−4.8 pt vs Q3 2024
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $17.85M | $17.96M | $10.35M | $14.18M |
| Net Income | $2.36M | $3.24M | -$1.85M | -$3.57M |
| EPS Diluted | $0.03 | $0.03 | -$0.04 | -$0.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR